A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Amin, A.; Ernstoff, M. S.; Infante, J. R.; Heng, D. Y. C.; Rini, B. I.; Plimack, E. R.; McDermott, D. F.; Kollmannsberger, C. K.; Reaume, M. N.; Spratlin, J. L.; Knox, J. J.; Voss, M. H.; Pal, S. K.; Shen, Y.; Dhar, A.; Hammers, H. J. |
| Abstract Title: | A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in combination with sunitinib, pazopanib, or ipilimumab in patients (pts) with metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 31 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2013 May 31-Jun 4 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2013-05-20 |
| Language: | English |
| ACCESSION: | WOS:000335419605453 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2013.31.15_suppl.tps4593 |
| Notes: | Meeting Abstract: TPS4593 -- Source: Wos |
